IDIOPATHIC RECURRENT PERICARDITIS REFRACTORY TO COLCHICINE TREATMENT CAN REVEAL TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PERIODIC SYNDROME


Interdepartmental Research Center of Systemic Autoimmune and Autoinflammatory Diseases, Unit of Rheumatology, Policlinico Le Scotte, University of Siena, Siena; 1Department of Evolutionary Biology, University of Siena, Siena; 2Department of Paediatrics, Rheumatology Unit, Anna Meyer Children’s Hospital and University of Florence; 3Interdepartmental Research Center of Systemic Autoimmune and Autoinflammatory Diseases, Unit of Immunological Sciences, Policlinico Le Scotte, University of Siena, Siena; 4UOC of Rheumatology, S. Camillo-Forlanini Hospital, Rome, Italy

Received May 8, 2009 – Accepted August 25, 2009

The first two authors contributed equally to this study

Recurrences develop in up to 20-50% of patients with acute pericarditis. Although different causes of recurrent pericarditis have been identified, the etiology remains obscure in most cases which are therefore labelled as idiopathic. Autoinflammatory syndromes include familial Mediterranean fever (FMF), due to mutations in the MEFV gene, and tumor necrosis factor receptor-associated periodic syndrome (TRAPS), due to mutations in the TNFRSF1A gene. Recurrent pericarditis is a common feature of both conditions, but it rarely occurs alone. Colchicine is the standard treatment for FMF, while patients with TRAPS do not respond to colchicine therapy, but are responsive to corticosteroids. Based on the proven efficacy of colchicine in preventing polyserositis in FMF, colchicine has been proposed for the treatment of recurrent pericarditis and is able to decrease the recurrence rate. Our aim was to investigate the possible involvement of TNFRSF1A mutations in a group of patients with idiopathic recurrent pericarditis who were refractory to colchicine treatment. Thirty consecutive patients (17 males, 13 females) diagnosed with idiopathic recurrent pericarditis, who were characterized by a poor response to colchicine treatment, were enrolled in the study. Mutations of the TNFRSF1A gene were searched for by amplifying, using polymerase chain reaction (PCR), genomic DNA, and direct sequencing. TNFRSF1A mutations were found in 4 of the 30 patients. None of these 4 patients had a family history of recurrent inflammatory syndromes or history of pericarditis. One of the 4 patients had a novel heterozygous deletion (ΔY103-R104) and three patients carried a heterozygous low-penetrance R92Q mutation. Our data suggest that TRAPS should be kept in mind in the differential diagnosis of recurrent pericarditis, and mutation analysis of the TNFRSF1A gene should be considered, in addition to MEFV analysis, in patients of Mediterranean origin. A poor response to colchicine treatment and/or a steroid-dependence may be the clue to investigate TNFRSF1A mutations in patients with idiopathic recurrent pericarditis.

Key words: idiopathic recurrent pericarditis, TNFRSF1A mutation, tumor necrosis factor receptor-1 associated periodic syndrome, colchicine resistance, etanercept

Mailing address: Dr Luca Cantarini, Institute of Rheumatology, Policlinico “Le Scotte”, University of Siena, Viale Bracci 1, 53100 Siena, Italy Tel: +39 347 9385457 Fax: +39 577 40450 e-mail: cantariniluca@hotmail.com

Copyright © by BIOLIFE, s.a.s. This publication and/or article is for individual use only and may not be further reproduced without written permission from the copyright holder. Unauthorized reproduction may result in financial and other penalties

0394-6320 (2009)
Recurrences develop in 20-50% of patients with acute pericarditis (1). Clinical signs and symptoms of acute pericarditis are characteristic of pericardial disease and include elevation of inflammatory markers, precordial pain, fever, pericardial friction rub, dyspnea, and electrocardiogram changes. Clinical manifestations during recurrences are similar to the first episode, but the subsequent episodes are typically milder and may be limited to precordial pain only. The number of recurrences and the intervals between attacks can vary among patients. Recurrent pericarditis may be isolated or associated with autoimmune rheumatic diseases, viral or bacterial infections, and neoplastic diseases (2). Although many causes have been identified, the etiology of recurrent pericarditis remains obscure in most cases (2).

Recurrent pericarditis, in the form of recurrent polyserositis, is common in familial Mediterranean fever (FMF) (3) and other auto-inflammatory disorders, a group of diseases caused by primary dysfunction of the innate immune system and characterized by seemingly unprovoked attacks of fever in association with localized inflammation that can affect multiple organ systems (4).

Tumor necrosis factor receptor-1-associated periodic syndrome (TRAPS) is the most common auto-inflammatory autosomal dominant disorder. TRAPS is caused by mutations in the gene TNFRSF1A, located on chromosome 12p13, encoding the 55-kD receptor for tumor necrosis factor-α (TNF-α) (5). The disease is characterized by recurrent attacks of fever typically lasting from 1 to 3 weeks; in addition to fever, common clinical features include mainly periorbital edema, a migratory erythematous plaque simulating erysipelas with underlying myalgia, and arthritis or arthralgia; serous membrane inflammation is also possible (6-7). Patients with TRAPS, unlike those with FMF, respond poorly to colchicine treatment, but are responsive to corticosteroids (8).

Although few patients with isolated serosal pericardial involvement carrying mutations in TNFRSF1A have been described (6), to the best of our knowledge no studies have been published on TNFRSF1A gene mutations in patients with idiopathic recurrent pericarditis. Our aim is to investigate the possible involvement of TNFRSF1A gene mutations in a group of patients with idiopathic recurrent pericarditis, who were refractory to colchicine treatment.

**MATERIALS AND METHODS**

**Patients**

We enrolled 30 consecutive patients (17 males, 13 females) diagnosed with idiopathic recurrent pericarditis who were characterized by a poor response to colchicine treatment at standard dose (1-2 mg/day). All patients were seen between September 2005 and November 2008 in our Institution, and were part of a larger cohort of patients treated for idiopathic recurrent pericarditis. Table I summarizes the main characteristics of the cohort of patients enrolled in our study.

Each patient underwent detailed examinations in order to rule out underlying diseases such as infections, connective tissue disorders and malignancies. None of the patients' past medical history was relevant for cardiac surgery or radiation therapy. Criteria for the diagnosis of recurrent pericarditis were: a) a documented first attack of acute pericarditis according to accepted diagnostic criteria (fever, pericardial friction rub, electrocardiographic changes, echocardiographic evidence of pericardial effusion, increases in the white blood cell count and/or erythrocyte sedimentation rate (ESR) and/or C-reactive protein (CRP) and/or serum amyloid A (SAA); and b) evidence of at least one recurrence.

Recurrence was documented by pain and one or more of the following signs: fever, pericardial friction rub, electrocardiographic changes, echocardiographic evidence of pericardial effusion, and elevations in the white blood cell count or ESR or CRP or SAA. Resistance to colchicine was defined as an unfavorable clinical response with persistence or recurrence of fever and pericardial effusion appearance or worsening during treatment. All patients were Caucasians of Italian ancestry; they all provided written consent for genetic testing, in accordance with the Helsinki Declaration and local Ethical Committee regulations.

**DNA extraction**

Mononuclear cells were purified from peripheral blood from healthy donors and patients (with informed consent) by density gradient centrifugation on Ficoll-Paque (Amersham Biosciences, Buckinghamshire, UK), using a Beckman GS-6R tabletop centrifuge (Beckman Coulter SpA, Milan, Italy). Cells were washed 2 X in phosphate buffered saline (PBS), resuspended in RPMI 1640 (Invitrogen Ltd, Paisley, UK) (buffered with sodium bicarbonate to pH 7.2) supplemented with 7.5% fetal calf serum (FCS) (HyClone, Thermofisher Scientific Inc, SouthLogan, UT), plated in plastic flasks (Sarstedt AG,
Fig. 1. A) DNA sequence electropherograms demonstrating the R92Q mutation in TNFRSF1A. WT, wild type. Sequence electropherograms of TNFRSF1A exon 4 PCR amplification products from healthy donor and patient. The arrow indicates the heterozygous G/A substitution resulting in the exchange of arginine for glutamine at position 92. B) DNA sequence electropherograms demonstrating the E148Q mutation in MEFV. WT, wild type. Sequence electropherograms of MEFV exon 2 PCR amplification products from healthy donor and patient. The arrow indicates the heterozygous G/C substitution resulting in the exchange of glutamic acid for glutamine at position 148.

Numbrecht, Germany) and incubated overnight at 37°C in a humidified atmosphere with 5% CO₂. Non-adherent cells, which consisted principally of peripheral blood lymphocytes (PBL), were centrifuged and resuspended in fresh RPMI 1640 supplemented with 7.5% FCS. Genomic DNA was isolated from peripheral blood lymphocytes of patients and healthy controls using QIAamp DNA mini Kit (Qiagen, Hilden Germany).

Genomic DNA amplification and mutation detection
The TNFRSF1A gene exons 2, 3, 4 and 6, which encode for the extracellular domain of the 55-kD receptor for TNF-α and the MEFV gene exons 2, 3, and 10, where the majority of known mutations are found, were amplified by polymerase chain reaction (PCR) using Expand High Fidelity PCR System (Roche, Germany). PCR products were purified using Wizard SV Gel and PCR Clean-Up System (Promega, Madison, WI, USA). Sequencing was carried out on the ABI 3730 DNA analyzer (Bio-Fab Research srl, Italy) using the same primers as those used in the PCR.

Restriction analysis of the Y103-R104 deletion
PCR of TNFRSF1A (exon 4) was performed in healthy donor and patient. The 332 basepair amplicons were then digested by Rsal restriction enzyme (Fermentas) according to the manufacturer’s instructions.

RESULTS
Out of 30 patients tested, four carried a mutation in the TNFRSF1A gene. Three of these (patients 12, 17 and 26 in Table 1) carried a heterozygous low-penetrance R92Q mutation (Fig. 1A), and one (patient 4 in Table 1) carried a novel heterozygous deletion (ΔY103-R104) (Fig. 2). The presence of the Y103-R104 deletion was further confirmed by restriction analysis carried out with Rsal restriction enzyme; in fact, deletion destroys an Rsal restriction site (GT↓
Fig. 2. Identification of novel mutation in exon 4 of the TNFRSF1A gene. DNA Sequence electropherograms of TNFRSF1A exon 4 PCR amplification product in forward (left) and reverse (right) from healthy donor (top) and patient (bottom). The patient presents six nucleotide heterozygous deletion (TACCGG nucleotide sequence) resulting in an electropherogram shift. This deletion causes the loss of tyrosine and arginine aminoacid at position 103 and 104, respectively (ΔY103-R104).

Fig. 3. Restriction analysis of the Y103-R104 deletion by RsaI restriction enzyme. PCR amplification TNFRSF1A exon 4 was performed in healthy donor (I) and patient (II). PCR product digestion by RsaI restriction enzyme resulted in two bands of 145 and 187 base pairs and three bands of 145, 187 and 332 base pairs in healthy donor (III) and patient (IV), respectively.

AC) (Fig. 3). All four patients were diagnosed with TRAPS. The mother, father and brother of patient 4 were clinically healthy and did not carry the mutation, indicating that the mutation is likely to have occurred de novo. The father of patient 12, the father of patient 17 and the mother of patient 26 also carried the mutation R92Q, but they were all clinically healthy. Patient 12 also carried a low-penetrance mutation E148Q in the MEFV gene (Fig. 1B), not carried by the parents, but was clinically diagnosed with TRAPS based on poor response to colchicine, the duration of fever attacks (> 2 weeks), and late onset of symptoms (34 years).

These four patients, who, like all the others in the study, had a poor response to colchicine, were selected for treatment with the tumor necrosis factor (TNF)-α neutralizing agent, etanercept (25 mg twice weekly). Three additional patients who did not carry mutations had increased (> 100 mg/L) levels of circulating SAA, measured at least three times also during symptom free intervals. Two of them (patients 9 and 13 in Table I) were successfully treated with anakinra (100 mg/daily), a recombinant human interleukin-1 receptor antagonist, while the third patient's parents refused this off-label treatment. In the remaining cases indomethacin (50-150 mg/daily) was added to colchicine. In a few patients (patients 11, 16, 19 and 21 in Table I) a further addition of low-dose prednisone was required in order to prevent recurrences. Eventually, all patients achieved good disease control. At the time of genetic testing all patients were taking colchicine 1-2 mg/daily.
Table I. Demographic, genetic and laboratory characteristics of patients.

<table>
<thead>
<tr>
<th>Pt</th>
<th>Age at testing/Age at onset (yrs)</th>
<th>Sex</th>
<th>SAA (mg/L)</th>
<th>Mutations in TNFRSF1A</th>
<th>Mutations in MEFV</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>14/12</td>
<td>F</td>
<td>158</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>28/27</td>
<td>F</td>
<td>58</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>37/35</td>
<td>M</td>
<td>28</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>28/13</td>
<td>M</td>
<td>181</td>
<td><strong>Delta Y103-R104 heterozygous</strong></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>26/22</td>
<td>M</td>
<td>42</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>42/35</td>
<td>F</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>22/17</td>
<td>M</td>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>34/31</td>
<td>M</td>
<td>42</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>27/24</td>
<td>F</td>
<td>146</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>39/36</td>
<td>F</td>
<td>44</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>59/51</td>
<td>F</td>
<td>88</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>50/34</td>
<td>M</td>
<td>138</td>
<td><strong>R92Q heterozygous</strong></td>
<td><strong>E148Q homozygous</strong></td>
</tr>
<tr>
<td>13</td>
<td>56/49</td>
<td>M</td>
<td>128</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>32/29</td>
<td>F</td>
<td>16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>29/24</td>
<td>M</td>
<td>34</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>48/43</td>
<td>M</td>
<td>68</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>32/28</td>
<td>F</td>
<td>112</td>
<td><strong>R92Q heterozygous</strong></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>16/13</td>
<td>M</td>
<td>26</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>36/35</td>
<td>F</td>
<td>98</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>24/21</td>
<td>M</td>
<td>48</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>36/32</td>
<td>M</td>
<td>67</td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>41/37</td>
<td>F</td>
<td>59</td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>50/54</td>
<td>M</td>
<td>76</td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>23/22</td>
<td>M</td>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>15/13</td>
<td>M</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>41/38</td>
<td>F</td>
<td>121</td>
<td><strong>R92Q heterozygous</strong></td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>53/50</td>
<td>F</td>
<td>9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>29/28</td>
<td>M</td>
<td>39</td>
<td></td>
<td></td>
</tr>
<tr>
<td>29</td>
<td>34/32</td>
<td>M</td>
<td>24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>17/16</td>
<td>F</td>
<td>26</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The table summarizes data from the entire cohort of patients enrolled. Gender, age at disease onset, age at the time of genetic testing and the circulating levels of serum amyloid A are shown. The results of genetic testing for mutations of the gene responsible for the tumor necrosis factor-α receptor-associated periodic syndrome (TNFRSF1A gene) and of the familial Mediterranean fever (MEFV gene) are also listed. List of abbreviations: Pt = patient; yrs = years; SAA = Serum Amyloid A; F = female; M = male

After one year of follow-up the four patients with TRAPS who were treated with etanercept did not show signs of disease relapse, and in all four, SAA levels had already decreased to normal values a few weeks after the initiation of treatment. The same was true for the 2 patients treated with anakinra.
**DISCUSSION**

Recurrences develop in 20-50% of adult patients with acute pericarditis (1). The aetiology of acute pericarditis and the cause of the recurrences remain obscure in most cases, which are thus labeled as idiopathic. Autoimmune responses may play a role in the pathogenesis of recurrent pericarditis (9). Other mechanisms that have been hypothesized in the pathogenesis include insufficient treatment during the first episode, possible re-infections and augmented viral DNA/RNA replication in pericardial tissue as possible consequences of long-term treatment with steroids (10).

Recurrent pericarditis and other recurrent serositis, often in the form of polyserositis, are common in FMF and TRAPS (3, 6-7); furthermore, patients with isolated recurrent pericarditis have been reported both in FMF (11) and in TRAPS (6). Dodè et al. recently described two patients presenting recurrent pericarditis as the sole clinical manifestation of TRAPS and carrying the low-penetrance mutations R92Q and P46L. In FMF, the incidence of pericardial involvement has been reported in 1.4% of cases in a series (12), but the incidence rises to 27% in echocardiographic studies (3).

Recently, Brucato et al. investigated the presence of FMF in two series of Italian patients with recurrent pericarditis; mutations in MEFV were searched for respectively in 23 and 61 patients, but never found (1, 13). In neither trial was genetic testing for mutations in the TNFRSF1A gene carried out. In our study we found a high incidence of TNFRSF1A mutations, in comparison to the absence of MEFV mutations, which may be due to the inclusion criteria and demographic characteristics of patients: 1) the enrolment of patients unresponsive to colchicine, which ruled out the majority of FMF patients that are typically responsive to colchicine (14); 2) the age of disease onset in most cases in our series was > 20 years, a highly unlikely occurrence in FMF.

TNFRSF1A is a transmembrane glycoprotein consisting of an extracellular region characterized by a distinct pattern of 4 cysteine-rich domains (CRDs 1-4), a transmembrane region, and an intracellular death domain (DD), which promotes TNFRSF1A signaling (15). The binding site for TNFα is formed by CRD2 and CRD3 (16) while CRD1 is the pre-ligand assembly binding domain and is thought to mediate TNFRSF1A self-assembly (17). More than 40 individual mutations have been identified, the majority of which is localised in the CRD1 and CRD2 domains. Most mutations described involve cysteine residues and are associated with a higher disease penetrance; however several variants involving other residues have been reported (18). In vitro studies suggest that these TRAPS-associated TNFRSF1A mutations are responsible for altered TNFRSF1A expression, impaired TNF-α binding and shedding (5), defective trafficking (19-20) and abnormal apoptosis (21-22).

Three of our patients carried the R92Q mutation in the TNFRSF1A gene and patient 4 carried a novel deletion (ΔY103-R104) in the CRD3 domain of TNFRSF1A that might be involved in receptor shedding, thus affecting TNFRSF1A membrane localization, or other receptor functions. The actual functional implication of this deletion is under investigation. The R92Q mutation is a low-penetrance allele common in patients of Mediterranean origin and has been found in 1.8% of Caucasian patients with recurrent inflammatory syndromes. R92Q mutation may cause a milder disease and may often be associated with an oligosymptomatic course (7, 23). The clinical phenotype of TRAPS is expanding, and since the discovery of TNFRSF1A, several studies have indicated that the low-penetrance TNFRSF1A variants might contribute to atypical inflammatory responses in TRAPS, including cardiac diseases (myocarditis and pericarditis) (6, 24), as in three of our cases.

Based on the proven efficacy of colchicine in preventing polyserositis in FMF, colchicine has been proposed for the treatment of recurrent pericarditis and is able to decrease the recurrence rate (25). However, patients with TRAPS are characterized by a poor response to colchicine and are typically responsive to corticosteroid administration (8), although steroids do not seem to protect completely from the risk of amyloidosis which occurs in up to 25% of patients (26). Although TNF-α levels are not usually significantly elevated in TRAPS patients compared with healthy controls, etanercept has been shown to elicit a beneficial response in patients with TRAPS-related amyloidosis (27); it can reduce
corticosteroid requirement and also prevent flare-ups (28). Accordingly, our patients were successfully treated with etanercept.

The patients who did not carry mutations, but persistently showed elevated circulating SAA levels, were considered to be affected by an unrecognized autoinflammatory disorder, since a large percentage of these patients demonstrated an elevated acute phase response between clinically symptomatic attacks (7). The choice of anakinra in our 2 patients proved successful, in accordance with recent published data (29), and was based on the demonstrated efficacy of anakinra in the treatment of a large spectrum of autoinflammatory diseases (30-31).

In conclusion, our preliminary data suggest that TRAPS should be kept in mind in the differential diagnosis of recurrent pericarditis, and mutation analysis in TNFRSF1A should be considered, in addition to MEFV analysis, in patients of Mediterranean origin. A poor response to colchicine treatment and/or a steroid-dependence may be the clue to investigate TNFRSF1A mutations in patients with idiopathic recurrent pericarditis. Furthermore, the discovery of TNFRSF1A mutations may have relevant clinical implications for patients, since etanercept is still to be considered the first-line therapy for TRAPS, although its long-term benefit has yet to be fully elucidated.

REFERENCES


